Shots:

• The designation is based on the P-III JUPITER-02 trial evaluating toripalimab + CT vs CT alone in patients with NPC. The result was presented at ASCO 2021
• The results demonstrated an improvement in PFS. The trial also meets 2EPs of PFS assessed by the investigator and ORR as assessed by BIRC including higher DoR; DCR & OS rates while safety profile is consistent with that observed in previously reported clinical trials
• The BLA submission is expected to complete in Q3’21 for toripalimab + CT as 1L NPC and for toripalimab monothx. as 1L & 2L NPC. The therapy has received FTD for the treatment of mucosal melanoma and ODD for NPC- mucosal melanoma- and soft tissue sarcoma

  | Ref: Globe Newswire | Image: PR Newswire